Envoy Medical (COCH) Trading Update
- Current Price: USD 0.60
- 24‑hour Performance: Up 1.89 % as of 03:12 PM Central Europe, Friday 23 Oct 2026.
- Volume: USD 46.7 k traded in the last 24 hours.
- Shares Outstanding: 77.4 million.
- Market Capitalisation: USD 50.1 million.
- Year‑to‑Date Performance: Down 9.51 % since the end of September.
- Simple Moving Average (200 days): USD 0.69.
- 52‑Week High: USD 0.95 on 17 Mar 2026.
- 52‑Week Low: USD 0.36 on 11 Feb 2026.
Peer Performance (24‑hour snapshot)
| Ticker | 24‑hour Change | Current Price | Market Capitalisation |
|---|---|---|---|
| CITR (Citrotech) | +1.54 % | USD 2.65 | USD 59.5 million |
| BTCS (Btcs) | +2.70 % | USD 1.10 | USD 59.8 million |
| GOSS (Gossamer Bio) | +2.19 % | USD 9.46 | USD 59.9 million |
| GC3.F (Novonix) | –1.48 % | EUR 0.05 | EUR 51.9 million |
| CRBU (Caribou Biosciences) | +4.82 % | USD 0.56 | USD 58.4 million |
Recent Corporate Actions (Envoy Medical)
- Financial Position: The company reported a current market cap of USD 50.1 million with 77.4 million shares outstanding.
- Trading Activity: USD 46.7 k worth of shares were exchanged during the latest 24‑hour period.
- Historical Performance: The stock has declined 9.51 % since the close of September 2026.
Company Overview
Envoy Medical, Inc. is headquartered in St. Paul, United States. The firm specializes in medical technologies that address hearing loss across the spectrum. Its stated mission is to transform the hearing industry by aligning provider and patient needs with appropriate hearing devices. The company trades on the Nasdaq stock exchange and provides additional information on its website at www.envoymedical.com .
Key Takeaways
- Envoy Medical’s share price increased modestly in the most recent trading session, reaching USD 0.60.
- The company’s market cap and trading volume remain relatively small compared to its peers.
- Recent peer activity shows a mix of gains and declines, with Caribou Biosciences and Btcs posting the strongest gains in the last 24 hours.
- Envoy Medical continues to focus on expanding its product portfolio within the hearing aid sector, as indicated in its corporate communications.